Envoy Medical, Inc. (NASDAQ:COCH – Free Report) – Research analysts at HC Wainwright lifted their FY2026 EPS estimates for shares of Envoy Medical in a research note issued on Monday, November 9th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($2.61) per share for the year, up from their prior estimate of ($3.10). HC Wainwright currently has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Envoy Medical’s current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Envoy Medical’s Q4 2026 earnings at ($0.64) EPS, Q1 2027 earnings at ($0.64) EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.54) EPS, Q4 2027 earnings at ($0.50) EPS and FY2027 earnings at ($2.25) EPS.
Envoy Medical (NASDAQ:COCH – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.17. The business had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.09 million. Envoy Medical had a negative return on equity of 5,250.23% and a negative net margin of 9,026.41%.
Several other analysts also recently issued reports on the company. Loop Capital set a $20.00 target price on Envoy Medical in a research note on Monday, July 27th. Lake Street Capital upped their price target on Envoy Medical from $2.50 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, October 27th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Envoy Medical in a research report on Monday, October 19th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $21.00.
View Our Latest Stock Analysis on Envoy Medical
Envoy Medical Stock Down 2.5%
Shares of Envoy Medical stock opened at $6.92 on Wednesday. The stock’s 50-day simple moving average is $6.81 and its 200-day simple moving average is $6.88. Envoy Medical has a 52 week low of $3.63 and a 52 week high of $9.54. The company has a market capitalization of $53.42 million, a price-to-earnings ratio of -1.50 and a beta of 2.03.
Envoy Medical News Roundup
Here are the key news stories impacting Envoy Medical this week:
- Positive Sentiment: Envoy Medical regained compliance with Nasdaq’s $1 minimum-bid-price rule after its shares closed above that threshold for 10 consecutive trading days, easing a listing-related concern. Article: Envoy Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Positive Sentiment: HC Wainwright reiterated its Buy rating and $18 price target. The firm also raised its FY2026 EPS estimate to a loss of $2.61 per share from a projected loss of $3.10, implying a less severe expected annual loss. HC Wainwright analyst recommendations
- Positive Sentiment: Reported short interest fell 84.4% between October 15 and October 30, to 89,915 shares. Lower short positioning may reduce potential selling pressure, though the figures are dated and another report gave a conflicting November tally. Article: Envoy Medical Shares Shorted
- Negative Sentiment: HC Wainwright cut its EPS forecasts for every quarter from Q4 2026 through Q4 2027, and lowered its FY2027 estimate to a loss of $2.25 per share from $1.80. These revisions point to greater anticipated losses over the near-term outlook and could weigh on sentiment despite the maintained Buy rating.
Envoy Medical Company Profile
Envoy Medical is a medical technology company focused on developing fully implanted hearing devices for people with sensorineural hearing loss. Unlike conventional hearing aids and many cochlear implants, its technology is designed to be placed beneath the skin, with no external wearable sound processor. The company’s lead product is the Acclaim Cochlear Implant, a fully implanted cochlear implant intended to address moderate-to-profound sensorineural hearing loss in adults. The system is designed to use the body’s natural anatomy to capture sound and convert it into electrical signals that stimulate the auditory nerve.
Featured Articles
- Five stocks we like better than Envoy Medical
- Poll Reveals: Which States Are Most Prepared for a Crisis? [2026]
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
Receive News & Ratings for Envoy Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envoy Medical and related companies with MarketBeat.com's FREE daily email newsletter.
